Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Starling Oncology, Inc. (STLN)

Starling Oncology director Brad Hively will not seek re-election in 2027

Neutral Impact 3 of 5 leadership Written later

Starling Oncology director Brad Hively told the company on September 1, 2026 that he will not stand for re-election to the Board at the 2027 annual meeting. He remains a director until that meeting but immediately stepped down as Vice Chairman and from the Compliance Committee and other Board committees. The company says the decision did not stem from any disagreement over its operations, policies or practices.

Key points

  • Brad Hively will not stand for re-election to the Board at the 2027 annual meeting of stockholders.
  • Hively remains a director until the 2027 annual meeting, per the filing.
  • Effective immediately, Hively no longer serves as Vice Chairman or on the Compliance Committee or other Board committees.
  • The filing states the decision was not the result of any disagreement with the company.

The filing

CompanyStarling Oncology, Inc. (STLN)
Form8-K, current report
Filed with the SECSep 1, 2026, 8:41 PM ET
Accession number0001079973-26-001208

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.